Annexin A9 (ANXA9) biomarker and therapeutic target in epithelial cancer
Patent
·
OSTI ID:1055690
- El Cerrito, CA
- San Ramon, CA
- San Mateo, CA
- San Francisco, CA
Amplification of the ANXA9 gene in human chromosomal region 1q21 in epithelial cancers indicates a likelihood of both in vivo drug resistance and metastasis, and serves as a biomarker indicating these aspects of the disease. ANXA9 can also serve as a therapeutic target. Interfering RNAs (iRNAs) (such as siRNA and miRNA) and shRNA adapted to inhibit ANXA9 expression, when formulated in a therapeutic composition, and delivered to cells of the tumor, function to treat the epithelial cancer.
- Research Organization:
- University of California (Oakland, CA)
- Sponsoring Organization:
- USDOE
- DOE Contract Number:
- AC02-05CH11231
- Assignee:
- The Regents of the University of California (Oakland, CA)
- Patent Number(s):
- 8,198,254
- Application Number:
- 12/412,304
- OSTI ID:
- 1055690
- Country of Publication:
- United States
- Language:
- English
Similar Records
Breast cancer stem cells, EMT and therapeutic targets
Predictive and therapeutic markers in ovarian cancer
Small interfering RNA targeting ILK inhibits metastasis in human tongue cancer cells through repression of epithelial-to-mesenchymal transition
Journal Article
·
Fri Oct 10 00:00:00 EDT 2014
· Biochemical and Biophysical Research Communications
·
OSTI ID:22416786
Predictive and therapeutic markers in ovarian cancer
Patent
·
Tue Mar 26 00:00:00 EDT 2013
·
OSTI ID:1082960
Small interfering RNA targeting ILK inhibits metastasis in human tongue cancer cells through repression of epithelial-to-mesenchymal transition
Journal Article
·
Thu Aug 01 00:00:00 EDT 2013
· Experimental Cell Research
·
OSTI ID:22271327